# FDA Approves First Therapy for Patients Aged 8+ with Glycogen Storage Disease Type Ia

> fda · REPORTED · 2026-08-19

On August 19, 2026, the FDA approved the first-ever therapy indicated for patients aged 8 years and older with Glycogen Storage Disease Type Ia, a rare metabolic disorder, marking a significant regulatory milestone in rare disease treatment. This approval reflects the FDA's continued focus on rare pediatric and adult metabolic conditions with previously unmet needs.

About FDA / Glycogen Storage Disease Therapy: This approval addresses Glycogen Storage Disease Type Ia, a rare inherited metabolic disorder in which the body cannot properly regulate blood glucose, leading to dangerous hypoglycemia and long-term organ complications in affected patients.

- Company: FDA / Glycogen Storage Disease Therapy
- Sector: therapeutics
- Primary source: https://www.fda.gov/news-events/press-announcements

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.